MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB)*
Organization & Developments: Y-mAbs Therapeutics
Parents
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB)*
Children
2019: Y-mAbs Therapeutics: Impressive Data In Multiple Oncology Indications, Regulatory Submissions Loom_seekingalpha.com
2019: Y-mAbs Therapeutics' neuroblastoma vaccine nabs accelerated review status in U.S._seekingalpha.com
2020: FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma_ymabs
2020: Y-mAbs Is One To Accumulate Before PDUFA
2020: Y-mAbs Therapeutics: Further Upside After Approval
2022: Y-mAbs Therapeutics: Future Upside Dependent On Reinvigorating Danyelza Sales_ seekingalpha.com
2024: Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)_seekingalpha.com
2024: Y-mAbs Therapeutics: A Monoclonal Antibody Play_ seekingalpha.com
2025: Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials
Jumps
Finance & Acquisitions: Y-mAbs Therapeutics
Key People: Y-mAbs Therapeutics